Alys Pharmaceuticals, Inc., an immuno-dermatology startup with offices in Boston, Massachusetts, and Geneva, Switzerland, has been launched with a funding of $100 million from Medicxi.
Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics to develop its pipeline of 14 active programs, targeting multiple dermatological indications, including atopic dermatitis, vitiligo, psoriasis and mastocytosis.
Alys collaborates with organizations including the Swiss Federal Laboratories for Materials Science & Technology (Empa), Institut Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology, and others.
The clinical and scientific founders all have minority stakes in Alys and their expertise is leavened by experienced biopharma leadership, including co-founder and chief operating officer Thibaud Portal – formerly global head of prescription medicines at Galderma.
Francesco De Rubertis of Medicxi is the board chairman.
